CSF2 and Miyoshi myopathy: In advanced MM patients, T-VEC injections yielded a higher objective response rate (26% vs. 6%), complete response rate (11% vs. 1%), and durable response rate (a continuous response for at least 6 mo, 16% vs. 2%) compared to GM-CSF alone (p < 0.0001), with a trend towards higher OS (HR 0.79, 95% CI: 0.61–1.01) [68].